The treatment landscape for ovarian cancer has rapidly progressed in recent years, particularly with the discovery of antiangiogenic agents and the emergence of PARP inhibitors. Despite these advances, high recurrence rates and low cure rates remain a significant challenge and new treatments are needed. One potential target that has emerged in recent years is folate receptor α (FRα), which is overexpressed in more than half of high-grade serous ovarian cancers. Multiple agents that target FRα have been developed and are currently under investigation for the treatment of ovarian cancer. This article explores the evolving ovarian cancer therapeutic spectrum, with an emphasis on FRα and its potential role among the current treatment options.
... to read the full story